POZEN Announces November 8th Webcast Of Third Quarter 2012 Results And November 6th Presentation Of Phase 3 Results For PA32540 At AHA’s Scientific Sessions 2012
POZEN Inc. (NASDAQ: POZN),
a pharmaceutical company
committed to transforming medicine that transforms lives, announced
today that it plans to release third quarter 2012 results on November 8,
2012, before the market...
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release third quarter 2012 results on November 8, 2012, before the market opens. The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The third quarter 2012 earnings release will be accessible in the Media section of POZEN’s website. POZEN also will present the Phase 3 results for its PA32540 product candidate at the American Heart Association’s 2012 Scientific Sessions. POZEN will present on November 6, 2012 at 3:00 p.m. (PT) at the Los Angeles Convention Center. About PA POZEN is creating a portfolio of integrated aspirin therapies – the PA product platform. The products in the PA portfolio are intended to significantly reduce GI ulcers and other GI complications compared to taking aspirin alone. The first candidates are PA32540, containing 325 mg of aspirin, and PA8140, containing 81 mg of aspirin. Both products are a coordinated-delivery tablet combining immediate-release omeprazole (40 mg), a proton pump inhibitor, layered around pH-sensitive aspirin. This novel, patented product is administered orally once a day and an indication will be sought for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers. About POZEN POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years. Funded by these milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.